Glucotrack's AI Lab Identified 45 Drug Opportunities for $33,000 in First Year

Glucotrack's AI-driven drug discovery lab screened over 45 therapeutic opportunities in its first year on a $33,000 budget.

A drug discovery lab running on roughly $33,000 identified more than 45 potential therapeutic assets in its first year — a fraction of what conventional biopharma pipeline-building typically costs. Glucotrack (NASDAQ: GCTK) announced the milestone on July 31, 2026, highlighting the performance of its ai2 Futures Lab, operated through its wholly owned subsidiary Lōkahi Therapeutics Inc., headquartered across Rutherford, N.J. and La Jolla, Calif. Of the 45-plus opportunities screened, five advanced into active company discussions. The assets under consideration represent more than $500 million in prior biopharmaceutical investment, suggesting the lab is identifying and recycling already-vetted compounds or programs rather than starting from scratch. The ai2 Futures Lab uses artificial intelligence to scan and evaluate potential drug candidates, positioning Glucotrack — primarily known as a continuous glucose monitoring company — as a player in broader AI-assisted drug discovery. The announcement frames the lab's first-year results as a proof of concept for a lower-cost model of building a pharmaceutical pipeline.

Why it matters

If replicable, an AI-driven pipeline model that identifies dozens of drug candidates for under $33,000 could significantly lower the barrier to entry in biopharma drug development. The approach may also offer a faster path to repurposing assets backed by hundreds of millions in prior industry investment.

What's next

The five therapeutic opportunities that advanced into active company discussions will be ones to watch for formal partnership announcements or development agreements.

Key facts

• The ai2 Futures Lab is operated by Lōkahi Therapeutics Inc., a wholly owned subsidiary of Glucotrack (NASDAQ: GCTK)
• In its first year, the lab identified more than 45 therapeutic opportunities on a budget of approximately $33,000
• Five of those opportunities advanced into active company discussions
• The assets under review represent more than $500 million in prior biopharmaceutical investment
• Glucotrack is headquartered across Rutherford, N.J. and La Jolla, Calif.
• The announcement was made July 31, 2026

Bias & framing notes

All three sources carry identical Business Wire press release text, meaning this is entirely company-issued promotional content with no independent journalism or third-party verification. Sources 1 and 2 (Post Register and Eagle Tribune) appear to have republished the wire without additional reporting. The figures cited — $33,000 budget, 45 opportunities, $500M prior investment — are unverified claims from Glucotrack itself and should be treated as such.

NewsClear — neutral news & congressional tracking · Bill of the Week